This article is a paid advertisement. ARU Global Inc. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of FendX Technologies Inc. (“FNDX”) and its securities, FNDX has provided the Publisher with a budget of approximately $500,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by FNDX) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP. The owner of ARU Global Inc. may be buying and selling shares of this issuer for its own profit. The Publisher has no information concerning share ownership by others in the profiled company FNDX. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

General Disclaimer

This article contains certain forward-looking statements within the meaning of Canadian securities legislation (the “Forward-looking Statements”), including with respect to: the plans of FNDX; expectations regarding industry trends, including with respect to the antimicrobial surface market, overall market growth rates and FNDX’s growth rates and growth strategies; that microbe repellent technology is a promising, high-growth industry; the use of available funds; the performance of FNDX’s business and operations; FNDX’s expectations regarding revenues, expenses and anticipated cash needs; the intention to grow FNDX’s business and operations; the expected timing and completion of FNDX’s near‑term objectives; laws and regulations and any amendments thereto applicable to FNDX; FNDX’s competitive advantages and business strategies; FNDX’s future product offerings; FNDX’s research and development initiatives and expected results thereof; FNDX’s growing patent portfolio; FNDX’s ability to enter into distribution, manufacturing and other business relationships; the potential of FNDX’s technology to protect against the spread of pathogens on surfaces through repelling bacteria and viruses that come in contact with its surface; that FNDX’s technology will bring significant value in controlling the spread of surface borne infectious diseases; that FNDX’s technology could be a key weapon to contribute in the battle against the growing global threat of infectious disease transmission; that FNDX’s technology could be deployed all over the world and it could save human lives; that spread of infectious disease is a deadly problem which is getting worse; that for businesses and governments looking to mitigate the spread of pathogens, FNDX’s nanotechnology could be part of the answer; if commercialized, FNDX’s technology could address the urgent need for innovative solutions to help control the spread of pathogens on surfaces – especially in healthcare; FNDX’s proprietary REPELWRAP™ film could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; FNDX’s nanotechnology has the potential to be applied to other types of surfaces and materials – such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like this offer potentially future upside, if FNDX can successfully adapt their technology; FNDX’s intention to initially target REPELWRAP^TM film towards healthcare settings and high traffic public touchpoints; that as FNDX continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, sports and entertainment, hospitality, and education sectors; the growing global commitment to reduce the spread of pathogens; and that REPELWRAP™ film will provide additional protection to current disinfecting practices to control the spread of pathogens. Although FNDX believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. FNDX cautions that forward-looking statements are based on the beliefs, estimates and opinions of FNDX’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement and Collaborative Research Agreement between FNDX and McMaster University and maintaining the License in good standing; inability of McMaster University to satisfy the terms under the License Agreement and Collaborative Research Agreement; completion of scale-up and development of a commercial product; research and development activities; reliance on grant funding; limited number of products; dependence on collaborative partners, licensors and others; changes and restrictions due to legal and regulatory requirements; dependence on each product’s acceptance in the market; possibility of smaller market opportunities than anticipated; increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of FNDX’s directors and officers; management’s efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of FNDX’s common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavourable research about FNDX; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; use of available funds; effect of general economic and political conditions; internal controls; and other risk factors set forth in FNDX’s final prospectus dated January 31, 2023 under the heading “Risk Factors” and other filings, publicly available through the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com. The reader is urged to refer to FNDX’s prospectus and other filings, publicly available through SEDAR at www.sedar.com for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, FNDX undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for FNDX to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any Forward-looking Statement. Any Forward-looking Statements contained in this article are expressly qualified in their entirety by this cautionary statement.

While the information contained in this article is believed to be accurate, FNDX expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this article or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this article are intended to be, nor shall be deemed to be, representations or warranties of FNDX. Where the information is from third-party sources, the information is from sources believed to be reliable, but FNDX has not independently verified any of such information contained herein.

This article is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any securities.